

#1

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Friday, October 4, 2024, 6:32:45 PM
Last Modified Date: Friday, October 4, 2024, 6:34:42 PM
Time Spent: 00:01:56
IP Address: 78.185.20.113

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Istanbul

S4 **State University**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	b
Lymphoma	c
Myeloma	c

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

60%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

12

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	2
Lymphoma count	5
Multiple myeloma count	5

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Other**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Other**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you had access to a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#2

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 10:11:58 AM
Last Modified Date: Tuesday, October 8, 2024, 10:14:00
Time Spent: 00:02:01
IP Address: 176.237.100.235

Page 1

Q1 Adult Hematology Clinic

What is your area of practice?

Q2 5–10 years

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Ankara

S4 Public Hospital

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	>10
Lymphoma	>10
Myeloma	>10

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

30

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

5

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of lymphoma cases

5

S9

How many of these patients are able to access CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

The respondent skipped this question

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Cost

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

Access to treatment

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#3

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 10:10:19 AM
Last Modified Date: Tuesday, October 8, 2024, 10:14:55
Time Elapsed: 00:04:35
IP Address: 176.216.170.59

Page 1

Q1 Pediatric Hematology/Oncology Clinic

What is your field of work?

Q2 >10 years

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Eskişehir

S4 State University

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	10
Lymphoma	3

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

10

S7
Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

2

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases	2
Lymphoma count	0
Multiple myeloma count	0

S9

How many of these patients have access to CAR-T therapy?

One

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

Pre-B ALL with post-transplant relapse

S11

Which CAR-T product was used?

Commercial Product (please specify the product name)	Chymera
--	---------

S12

Where did your patient receive CAR-T therapy?

Turkey (specify the center)	Spain
-----------------------------	-------

S13

How long after the indication arose did your patient receive CAR-T therapy?

Approximately 2 months

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Cost

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

Access to treatment

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#4

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 10:16:45 AM
Last Modified Date: Tuesday, October 8, 2024, 10:19:08 AM
Time Spent: 00:02:23
IP Address: 176.219.252.91

Page 1

S1 Adult Hematology Clinic

What is your area of practice?

S2 >10 years

How many years have you been working in the field of hematology?

S3 In which city is the institution where you work located?

Kocaeli

S4 State University

The institution you work for;

S5 How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	B
Lymphoma	C
Myeloma	C

S6 What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

40

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

4–5

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	1
Lymphoma count	3
Multiple myeloma count	3

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

The respondent skipped this question

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

Q17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#5

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 10:18:40 AM
Last Modified Date: Tuesday, October 8, 2024, 10:21:00 AM
Time Spent: 00:02:20
IP Address: 24.133.80.253

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

S2 **1–5 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

IZMIR

S4 **State University**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	15
Lymphoma	100
Myeloma	50

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

20–30%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

20

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	4
Lymphoma count	5
Multiple myeloma count	11

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#6

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 10:28:27 AM
Last Modified Date: Tuesday, October 8, 2024, 10:32:45 AM
Time Spent: 00:04:18
IP Address: 84.51.15.34

Page 1

Q1 **Pediatric Hematology/Oncology Clinic**

What is your field of work?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the organization you work for located?

ANTALYA

S4 **Private Hospital**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL **C**

S6
What are the relapse rates among patients with these disease groups treated at your clinic over the past year?

Since I work in the transplant unit, 85% of the patients are relapsed patients

S7
Based on current guidelines, how many of your patients required CAR-T therapy over the past year?

7–8

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	7
Lymphoma count	1
Multiple myeloma count	-

S9

The respondent skipped this question

How many of these patients have access to CAR-T therapy?

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Cost

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

Access to treatment

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#7

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 10:33:29 AM
Last Modified Date: Tuesday, October 8, 2024, 10:35:08
Time Spent: 00:01:39
IP Address: 149.140.236.203

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Edirne

S4 **State University**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at your clinic in the past year? (a) 5 b) 5–10 c) >10)

ALL	C
Lymphoma	C
Myeloma	C

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

30%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

20

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	5
Lymphoma count	5
Multiple myeloma count	5

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#8

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 10:33:19 AM
Last Modified Date: Tuesday, October 8, 2024, 10:36:32 AM
Time Spent: 00:03:13
IP Address: 178.244.3.13

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Kayseri

S4 **State University**

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at your clinic in the past year? (a) 5 b) 5–10 c) >10)

ALL	B
Lymphoma	C
Myeloma	C

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

40 40 50

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

30

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	5
Lymphoma count	15
Multiple myeloma count	10

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15	Insufficient technological infrastructure
------------	--

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16	Access issues
------------	----------------------

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17	Yes
------------	------------

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#9

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 10:39:42 AM
Last Modified Date: Tuesday, October 8, 2024, 10:42:08
Time Spent: 00:02:26
IP Address: 212.252.118.36

Page 1

Q1 **Adult Hematology Clinic**

In which field do you work?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Aydin

S4 **State University**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	C
Lymphoma	C
Multiple Myeloma	C

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

50%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

5

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of lymphoma cases 4

Multiple myeloma count 1

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

Which CAR-T product was used?

Commercial Product (please specify the product name) 0

Academic Production (specify center) 0

S12

Where did your patient receive CAR-T therapy?

Abroad (specify the center) 0

Turkey (specify the center) 0

Overseas clinical trial (please specify the center) 0

Work in Turkey (specify location) 0

S13

How long after the indication arose did your patient receive CAR-T therapy?

0

S14**Yes**

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#10

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 10:15:06 AM
Last Modified Date: Tuesday, October 8, 2024, 10:42:47 AM
Time Spent: 00:27:40
IP Address: 149.140.113.115

Page 1

Q1 **Adult Hematology Clinic**

What is your field of work?

Q2 **5–10 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Istanbul

S4 **Foundation University**

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	14
Lymphoma	50
Myeloma	120

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

50

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

20

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	3
Lymphoma count	9
Multiple myeloma count	8

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15	Insufficient technological infrastructure
------------	--

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16	Access issues
------------	----------------------

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17	Yes
------------	------------

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#11

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 10:44:47 AM
Last Modified Date: Tuesday, October 8, 2024, 10:47:20 AM
Time Spent: 00:02:32
IP Address: 85.237.210.100

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **1–5 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Mersin

S4 **State Hospital**

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	a
Lymphoma	c
Myeloma	c

S6

What are the relapse rates among patients with these disease groups treated at your clinic over the past year?

15%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

3

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases	0
Lymphoma count	3
Multiple myeloma count	0

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

Which CAR-T product was used?

Commercial Product (please specify the product name)	None
Academic Production (specify center)	None

S12

Where did your patient receive CAR-T therapy?

Abroad (specify the center)	None
Turkey (specify the center)	None
Overseas clinical trial (please specify the center)	None
Work in Turkey (specify location)	None

S13

How long after the indication arose did your patient receive CAR-T therapy?

None

S14**Yes**

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Insufficient technological infrastructure**

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16**Access issues**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#12

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 10:55:15 AM
Last Modified Date: Tuesday, October 8, 2024, 10:57:48
Time Spent: 00:02:33
IP Address: 194.27.109.109

Page 1

Q1 **Pediatric Hematology/Oncology Clinic**

What is your field of work?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Izmir

S4 **State University**

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at your clinic in the past year? (a) 5 b) 5–10 c) >10)

ALL	c
Lymphoma	-
Myeloma	-

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

10%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

1

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases	1
Lymphoma count	-
Multiple myeloma count	-

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

The respondent skipped this question

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#13

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 10:59:03
Last Modified Date: Tuesday, October 8, 2024, 11:04:45 AM
Time Spent: 00:05:41
IP Address: 46.106.243.50

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Istanbul

S4 **Private Hospital**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	C
Lymphoma	C
Myeloma	C

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?
B ALL 50% NHL 20% MM 20%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

10

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	7
Lymphoma count	2
Multiple myeloma count	1

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

4—all received it abroad for NHL

S11

Which CAR-T product was used?

Commercial Product (please specify the product name)	Yescarta
Academic Production (specify center)	Hamburg

S12

Where did your patient receive CAR-T therapy?

Private treatment abroad (please specify the center)	Hamburg
--	---------

S13

How long after the indication arose did your patient receive CAR-T therapy?

6 months

S14**Yes**

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**No**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#14

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 11:14:38 AM
Last Modified Date: Tuesday, October 8, 2024, 11:19:09 AM
Time Spent: 00:04:31
IP Address: 195.87.13.21

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Istanbul

S4 **Private Hospital**

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	c
Lymphoma	c
Myeloma	c

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

ALL: 50%, LY: 20%, MM: 30–40%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

20

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases	10
Lymphoma count	5–6
Multiple myeloma count	5–6

S9

How many of these patients have access to CAR-T therapy?

1

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

3

S11

Which CAR-T product was used?

Commercial Product (please specify the product name)	1 commercial (Axicell)
Academic Production (specify center)	2 academic

S12

Where did your patient receive CAR-T therapy?

Paid treatment abroad (specify center)	1 patient, Hamburg
Turkey (specify the center)	Acibadem (2)

S13

How long after the indication arose did your patient receive CAR-T therapy?

Acibadem: 1 month and 4 months (delayed)

S14**Yes**

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#15

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 11:33:20 AM
Last Modified Date: Tuesday, October 8, 2024, 11:36:17 AM
Time Spent: 00:02:57
IP Address: 193.255.55.192

Page 1

Q1 Adult Hematology Clinic

What is your field of work?

Q2 5–10 years

How many years have you been working in the field of hematology?

S3 In which city is the institution where you work located?

Denizli

S4 State University

The institution you work for;

S5 How many patients with pre-B-ALL, B-NHL, and myeloma have been treated at your clinic in the past year? (a) 5 (b) 5–10 (c) >10

ALL	a
Lymphoma	c
Myeloma	c

S6 What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

30%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

5

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases	0
Lymphoma count	3
Multiple myeloma count	2

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#16

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 10:24:30 AM
Last Modified Date: Tuesday, October 8, 2024, 11:40:36 AM
Time Spent: 01:16:05
IP Address: 188.57.135.247

Page 1

Q1 Pediatric Hematology/Oncology Clinic

What is your field of work?

Q2 5–10 years

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Adana

S4 Private Hospital

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	10
Lymphoma	5
Myeloma	0

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

15%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

1

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases

1

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Insufficient technological infrastructure

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16

Access issues

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#17

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 2:39:10 PM
Last Modified Date: Tuesday, October 8, 2024, 2:40:51 PM
Time Spent: 00:01:41
IP Address: 194.27.118.1

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **1–5 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Bursa

S4 **State University**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	c
Lymphoma	c
Myeloma	c

S6
What are the relapse rates among patients with these conditions treated at your clinic over the past year?

45%

S7

Based on current guidelines, how many of your patients required CAR-T therapy over the past year?

5

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	2
Lymphoma count	2
Multiple myeloma count	1

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#18

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 2:35:18 PM
Last Modified Date: Tuesday, October 8, 2024, 2:42:40 PM
Time Spent: 00:07:21
IP Address: 194.27.50.136

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Manisa

S4 **State University**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	b
Lymphoma	c
Myeloma	c

S6
What is the relapse rate among patients with these disease groups treated at your clinic in the past year?

I'm not sure

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

3–4

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of lymphoma cases

3–4

S9

How many of these patients are able to access CAR-T therapy?

none

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

None

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Lack of qualified personnel

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

Difficulty accessing treatment

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#19

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 3:16:37 PM
Last Modified Date: Tuesday, October 8, 2024, 3:19:04 PM
Time Spent: 00:02:27
IP Address: 92.61.2.42

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Ankara

S4 **State University**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	a
Lymphoma	b
Myeloma	c

S6
What is the relapse rate among patients with these disease groups treated at your clinic in the past year?

80%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

5

S8

Based on current guidelines, how do you determine which of your patients should receive CAR-T therapy based on their diagnoses?

Number of ALL cases	1
Lymphoma count	4
Multiple myeloma count	2

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

Which CAR-T product was used?

Commercial Product (please specify the product name)	0
Academic Production (specify center)	0

S12

Where did your patient receive CAR-T therapy?

Abroad (specify the center)	0
Turkey (specify the center)	0
Overseas clinical trial (please specify the center)	0
Work in Turkey (specify location)	0

S13

How long after the indication arose did your patient receive CAR-T therapy?

0

S14**Yes**

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#20

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 4:22:53 PM
Last Modified Date: Tuesday, October 8, 2024, 4:25:12 PM
Time Spent: 00:02:18
IP Address: 176.88.33.50

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Istanbul

S4 **Private Hospital**

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	C
Lymphoma	C
Myeloma	C

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

30–40%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

3–4

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	1
Lymphoma count	1
Multiple myeloma count	2

S9

How many of these patients have access to CAR-T therapy?

None

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

None

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#21

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 4:53:13 PM
Last Modified Date: Tuesday, October 8, 2024, 4:55:52 PM
Time Spent: 00:02:38
IP Address: 151.135.104.129

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Istanbul

S4 **State University**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	A
Lymphoma	C
Myeloma	C

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

25%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

15

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	1
Lymphoma count	5
Multiple myeloma count	9

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

No

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#22

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 5:20:57 PM
Last Modified Date: Tuesday, October 8, 2024, 5:25:26 PM
Time Spent: 00:04:29
IP Address: 31.223.33.140

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **5–10 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

ANKARA

S4 **Public Hospital**

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	C
Lymphoma	C
Myeloma	C

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

20–30%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

10%

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	10
Lymphoma count	10
Multiple myeloma count	5

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#23

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 6:38:07 PM
Last Modified Date: Tuesday, October 8, 2024, 6:41:03 PM
Time Spent: 00:02:55
IP Address: 176.88.72.233

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **5–10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Istanbul

S4 **Public Hospital**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	20
Lymphoma	90
Myeloma	60

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

20

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

10

S8

Based on current guidelines, how do you determine the distribution of your patients who you believe should receive CAR-T therapy according to their diagnoses?

Number of ALL cases	20%
Lymphoma count	70
Multiple myeloma count	10%

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15	Insufficient technological infrastructure
------------	--

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16	Access issues
------------	----------------------

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17	Yes
------------	------------

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#24

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 6:59:34 PM
Last Modified Date: Tuesday, October 8, 2024, 7:04:30 PM
Time Spent: 00:04:55
IP Address: 176.238.233.179

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Ankara

S4 **Public Hospital**

The institution where you work;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	C
Lymphoma	C
Myeloma	C

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

50%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

20

S8

Based on current guidelines, how do you determine which of your patients should receive CAR-T therapy based on their diagnoses?

Number of ALL cases	5
Lymphoma count	10
Multiple myeloma count	5

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#25

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 7:24:50 PM
Last Modified Date: Tuesday, October 8, 2024, 7:34:31 PM
Time Spent: 00:09:40
IP Address: 195.87.13.21

Page 1

Q1 **Pediatric Hematology/Oncology Clinic**

What is your field of work?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Istanbul (Question 4: public or private—if you have any questions, I am Prof. Rejin Kebudi—you can contact me)

S4 **Public University**

The institution where you work;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	3
Lymphoma	3

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

0

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

0

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases

2% (over the past 5 years)

S9

How many of these patients are able to access CAR-T therapy?

In the past 5 years, one received CAR-T therapy in Turkey and one in London

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

1 patient with high-risk ALL who received CAR-T after a second relapse following SCT (in London); 1 patient with CNS relapse of ALL who received CAR-T after a haploidentical SCT from the mother (in Turkey)

S11

Which CAR-T product was used?

Commercial Product (please specify the product name)

One received it in London

Academic production (specify center)

Acıbadem in Turkey also received it

S12

Where did your patient receive CAR-T therapy?

Abroad (specify the center)

London (GOS Hospital, Prof. Ajay Vora)

Turkey (private, please specify the center)

**Acıbadem (Prof. Gülyüz Öztürk, Prof. Ercüment Ovalı)
(partly private insurance, partly SGK)**

S13

How long after the indication arose did your patient receive CAR-T therapy?

Shortly

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16**Other**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you had access to a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#26

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 7:33:26 PM
Last Modified Date: Tuesday, October 8, 2024, 7:36:40 PM
Time Spent: 00:03:14
IP Address: 176.240.170.82

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Izmir

S4 **State University**

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	20
Lymphoma	80
Myeloma	60

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

ALL 40%, lymphoma 30%, myeloma 40%

S7

Based on current guidelines, how many of your patients should have received CAR-T therapy in the past year?

At least 10

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	3
Number of lymphomas	4
Multiple myeloma count	3

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#27

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 8:16:25 PM
Last Modified Date: Tuesday, October 8, 2024, 8:19:16 PM
Time Spent: 00:02:50
IP Address: 176.40.241.247

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Eskişehir

S4 **State University**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	B
Lymphoma	C
Myeloma	C

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

40

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

4

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases	2
Lymphoma count	2
Multiple myeloma count	0

S9

How many of these patients are able to access CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

Which CAR-T product was used?

Commercial Product (please specify the product name)	0
Academic Production (specify center)	0

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#28

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 8:27:15 PM
Last Modified Date: Tuesday, October 8, 2024, 8:30:30 PM
Time Spent: 00:03:14
IP Address: 88.227.75.84

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Ankara

S4 **Private Hospital**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	C
Lymphoma	C
Myeloma	C

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

50

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

20

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of Multiple Myeloma cases

100

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many patients have you treated with CAR-T therapy? (Please specify the disease diagnosis and the indication for CAR-T therapy)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Cost

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

Access to treatment

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#29

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 8, 2024, 11:15:41 PM
Last Modified Date: Tuesday, October 8, 2024, 11:21:08 PM
Time Spent: 00:05:26
IP Address: 176.40.242.179

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Ankara

S4 **Public Hospital**

The institution where you work;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	>10
Lymphoma	>10
Myeloma	>10

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

25–30%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

>10

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	5
Lymphoma count	5
Multiple myeloma count	>10

S9

How many of these patients have access to CAR-T therapy?

None

S10

How many patients have you treated with CAR-T therapy? (Please specify the diagnosis and the indication for CAR-T therapy)

None

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

The respondent skipped this question

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#30

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Wednesday, October 9, 2024, 6:47:56 AM
Last Modified Date: Wednesday, October 9, 2024, 6:51:06 AM
Time Spent: 00:03:09
IP Address: 31.223.42.17

Page 1

Q1 Pediatric Hematology/Oncology Clinic

In which field do you work?

Q2 >10 years

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Istanbul

S4 Foundation University

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at your clinic in the past year? (a) 5 b) 5–10 c) >10)

ALL b

Lymphoma b

S6
What is the relapse rate among patients with these disease groups treated at your clinic in the past year?

30%

S7
Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

5

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	3
Lymphoma count	2

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

Which CAR-T product was used?

Commercial Product (please specify the product name)	-
--	---

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Cost

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

Access to treatment

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#31

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Wednesday, October 9, 2024, 08:10:02
Last Modified Date: Wednesday, October 9, 2024, 08:12:00
Time Spent: 00:01:57
IP Address: 195.49.218.11

Page 1

Q1 Adult Hematology Clinic

What is your area of practice?

Q2 >10 years

How many years have you been working in the field of hematology?

S3 In which city is the institution where you work located?

Istanbul

S4 Foundation University

The institution you work for;

S5 How many patients with pre-B-ALL, B-NHL, and myeloma were treated at your clinic in the past year? (a) 5 b) 5–10 c) >10)

ALL	c
Lymphoma	c
Myeloma	c

S6 What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

15%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

5

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	%2
Lymphoma count	2
Multiple myeloma count	1%

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#32

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Wednesday, October 9, 2024, 11:35:24 AM
Last Modified Date: Wednesday, October 9, 2024, 11:51:36 AM
Time Spent: 00:16:12
IP Address: 176.236.167.158

Page 1

Q1 Adult Hematology Clinic

What is your field of work?

Q2 >10 years

How many years have you been working in the field of hematology?

S3 In which city is the institution where you work located?

Adana

S4 Foundation University

The institution you work for;

S5 How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	c
Lymphoma	c
Myeloma	c

S6 What are the relapse rates among patients with these disease groups treated at your clinic in the past year?
30–35%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

10

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	2
Lymphoma count	6
Multiple myeloma count	3

S9

The respondent skipped this question

How many of these patients have access to CAR-T therapy?

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

1 (Primary Mediastinal Large B-Cell Lymphoma)

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Cost

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16	The time it will take to access treatment
------------	--

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17	Yes
------------	------------

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#33

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Wednesday, October 9, 2024, 4:01:07 PM
Last Modified Date: Wednesday, October 9, 2024, 4:04:54 PM
Time Spent: 00:03:47
IP Address: 195.33.213.70

Page 1

Q1 Pediatric Hematology/Oncology Clinic

What is your field of work?

Q2 >10 years

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Ankara

S4 Private Hospital

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	c
Lymphoma	b

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

10%

S7
Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

5

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count

3

S9

How many of these patients have access to CAR-T therapy?

None

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

-

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Are the challenges in accessing CAR-T therapy preventing you from offering it as an option to your patients?

S15

Cost

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16

Access to treatment

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#34

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Wednesday, October 9, 2024, 9:20:47 PM
Last Modified Date: Wednesday, October 9, 2024, 9:22:09 PM
Time Spent: 00:01:21
IP Address: 78.185.20.113

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Istanbul

S4 **Public Hospital**

The institution where you work;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	8
Lymphoma	30
Myeloma	50

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

50

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

20

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	2
Lymphoma count	7
Multiple myeloma count	11

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Other**

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16**Access to treatment issue**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#35

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Wednesday, October 9, 2024, 9:49:38 PM
Last Modified Date: Wednesday, October 9, 2024, 9:51:42 PM
Time Spent: 00:02:03
IP Address: 78.182.134.2

Page 1

Q1 Adult Hematology Clinic

What is your area of practice?

Q2 1–5 years

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Istanbul

S4 State University

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	a
Lymphoma	c
Myeloma	c

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?
30–40%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

5

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases	2
Lymphoma count	2
Multiple myeloma count	1

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15	Insufficient technological infrastructure
------------	--

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16	Difficulty accessing treatment
------------	---------------------------------------

What is the reason for not referring a patient with a CAR-T indication for treatment?

S17	Yes
------------	------------

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#36

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Wednesday, October 9, 2024, 10:53:19 PM
Last Modified Date: Wednesday, October 9, 2024, 10:56:08 PM
Time Spent: 00:02:49
IP Address: 78.162.145.93

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **1–5 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Antalya

S4 **State University**

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at your clinic in the past year? (a) 5 b) 5–10 c) >10)

ALL	3
Lymphoma	40
Myeloma	25

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

Lymphoma: 10%, MM: 30%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

3

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of lymphoma cases 1

Multiple myeloma count 2

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

Which CAR-T product was used?

Commercial Product (please specify the product name) 0

Academic Production (specify center) 0

S12

Where did your patient receive CAR-T therapy?

Abroad (specify the center) 0

Turkey (specify the center) 0

Overseas clinical trial (please specify the center) 0

Work in Turkey (specify location) 0

S13

How long after the indication arose did your patient receive CAR-T therapy?

0

S14	Yes
Are the challenges in accessing CAR-T therapy preventing you from offering it as an option to your patients?	
S15	Insufficient technological infrastructure
What is the biggest obstacle to accessing CAR-T therapy in Turkey?	
S16	Access issues
What is your reason for not referring a patient with a CAR-T indication for treatment?	
S17	Yes
If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?	

#37

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Thursday, October 10, 2024, 05:59:08
Last Modified Date: Thursday, October 10, 2024, 06:02:01
Time Spent: 00:02:53
IP Address: 176.42.25.226

Page 1

Q1 Adult Hematology Clinic

What is your area of practice?

Q2 >10 years

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Ankara

S4 State University

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	>10
Lymphoma	>10
Myeloma	>10

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?
30%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

2

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases	0
Lymphoma count	1
Multiple myeloma count	1

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

Which CAR-T product was used?

Commercial Product (please specify the product name)	-
Academic Production (specify center)	-

S12

Where did your patient receive CAR-T therapy?

Abroad (specify the center)	-
Turkey (specify the center)	-
Overseas clinical trial (please specify the center)	-
Work in Turkey (specify location)	-

S13

How long after the indication arose did your patient receive CAR-T therapy?

-

S14**Yes**

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#38

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Thursday, October 10, 2024, 07:09:52
Last Modified Date: Thursday, October 10, 2024, 07:12:07
Time Spent: 00:02:14
IP Address: 88.253.232.51

Page 1

Q1 Adult Hematology Clinic

What is your area of practice?

Q2 5–10 years

How many years have you been working in the field of hematology?

S3 In which city is the institution where you work located?

Istanbul

S4 Public Hospital

The institution you work for;

S5 How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	B
Lymphoma	C
Myeloma	C

S6 What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

40

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

10

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	1
Lymphoma count	4
Multiple myeloma count	5

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Other**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment issue**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#39

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Thursday, October 10, 2024, 08:47:10
Last Modified Date: Thursday, October 10, 2024, 08:49:15
Time Spent: 00:02:05
IP Address: 5.229.28.66

Page 1

Q1 Adult Hematology Clinic

What is your area of practice?

S2 5–10 years

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Adana

S4 State University

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	C
Lymphoma	C
Myeloma	C

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

50%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

5

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	3
Lymphoma count	1
Multiple myeloma count	1

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Are the challenges in accessing CAR-T therapy preventing you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#40

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Friday, October 11, 2024, 11:36:07 AM
Last Modified Date: Friday, October 11, 2024, 11:40:48 AM
Time Spent: 00:04:41
IP Address: 88.255.66.69

Page 1

Q1 **Pediatric Hematology/Oncology Clinic**

What is your field of work?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Istanbul

S4 **State University**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL 22

S6
What are the relapse rates among patients with these disease groups treated at your clinic over the past year?

ALL: 10%

S7
Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

ALL: None required

S8

Based on current guidelines, how would you categorize the diagnoses of the patients you believe should receive CAR-T therapy?

Number of ALL cases

-

S9

How many of these patients are able to access CAR-T therapy?

-

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

-

S11

Which CAR-T product was used?

Commercial Product (please specify the product name)

-

Academic Production (specify center)

-

S12

Where did your patient receive CAR-T therapy?

Abroad (specify the center)

-

Turkey (specify the center)

-

Overseas clinical trial (please specify the center)

-

Work in Turkey (specify location)

-

S13

How long after the indication arose did your patient receive CAR-T therapy?

-

S14

The respondent skipped this question

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**The respondent skipped this question**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you had access to a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#41

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Monday, October 14, 2024, 3:48:36 PM
Last Modified Date: Monday, October 14, 2024, 3:50:20 PM
Time Spent: 00:01:43
IP Address: 176.89.153.37

Page 1

Q1

Pediatric Hematology/Oncology Clinic

What is your field of work?

Q2

>10 years

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Istanbul

S4

Public Hospital

The institution where you work;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	30
Lymphoma	20

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

1–2%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

1

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases

1

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Cost

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

Difficulty accessing treatment

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#42

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Monday, October 14, 2024, 4:02:31 PM
Last Modified Date: Monday, October 14, 2024, 4:12:38 PM
Time Spent: 00:10:06
IP Address: 193.255.224.84

Page 1

Q1 Pediatric Hematology/Oncology Clinic

What is your field of work?

Q2 >10 years

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Ankara

S4 State University

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	>10
Myeloma	0

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

We treated 5 ALL patients for relapse in the past year

S7
Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

2

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases

2**S9**

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

No

S11**The respondent skipped this question**

Which CAR-T product was used?

S12**The respondent skipped this question**

Where did your patient receive CAR-T therapy?

S13**The respondent skipped this question**

How long after the indication arose did your patient receive CAR-T therapy?

S14**Yes**

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#43

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Monday, October 14, 2024, 4:36:42 PM
Last Modified Date: Monday, October 14, 2024, 4:40:34 PM
Time Spent: 00:03:51
IP Address: 194.27.118.1

Page 1

Q1 Pediatric Hematology/Oncology Clinic

What is your field of work?

Q2 >10 years

How many years have you been working in the field of hematology?

S3 The respondent skipped this question

In which city is the institution where you work located?

S4 State University

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL 30

S6
What are the relapse rates among patients with these disease groups treated at your clinic over the past year?

N=2 ALL

S7
Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

1

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases

1

S9

How many of these patients have access to CAR-T therapy?

1

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

2

S11

Which CAR-T product was used?

Commercial Product (please specify the product name)

Kymeria

S12

Where did your patient receive CAR-T therapy?

Abroad (specify the center)

Frankfurt, Dr. Peter Bader; Barcelona, Dr. Susana Rives

S13

How long after the indication arose did your patient receive CAR-T therapy?

1–2 months

S14

No

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Insufficient technological infrastructure

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16

The respondent skipped this question

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you had access to a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#44

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Monday, October 14, 2024, 8:21:25 PM
Last Updated: Monday, October 14, 2024, 8:24:22 PM
Time Spent: 00:02:56
IP Address: 78.173.17.114

Page 1

Q1 **Pediatric Hematology/Oncology Clinic**

What is your field of work?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Afyonkarahisar

S4 **State University**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	b
Lymphoma	a
Myeloma	0

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?
0%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

0

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases	0
Lymphoma count	0
Multiple myeloma count	0

S9

How many of these patients have access to CAR-T therapy?

No patients met the criteria

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

Which CAR-T product was used?

Commercial Product (please specify the product name)	0
Academic Production (specify center)	0

S12

Where did your patient receive CAR-T therapy?

Abroad (specify the center)	0
Turkey (specify the center)	0
Overseas clinical trial (please specify the center)	0
Work in Turkey (specify location)	0

S13

How long after the indication arose did your patient receive CAR-T therapy?

Did not receive

S14**Yes**

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Insufficient technological infrastructure**

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16**Other**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you had access to a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#45

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Monday, October 14, 2024, 8:40:10 PM
Last Modified Date: Monday, October 14, 2024, 9:16:30 PM
Time Spent: 00:36:19
IP Address: 95.5.69.70

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **1–5 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Kayseri

S4 **State Hospital**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	c
Lymphoma	c
Myeloma	c

S6 **The respondent skipped this question**

What is the relapse rate among patients with these disease groups treated at your clinic in the past year?

S7 **The respondent skipped this question**

Based on current guidelines, how many of your patients required CAR-T therapy over the past year?

S8

The respondent skipped this question

How would you categorize your patients who you believe should receive CAR-T therapy based on their diagnoses according to current guidelines?

S9

The respondent skipped this question

How many of these patients are able to access CAR-T therapy?

S10

The respondent skipped this question

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

The respondent skipped this question

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

The respondent skipped this question

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

Access to treatment issue

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

The respondent skipped this question

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#46

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 07:28:32
Last Modified Date: Tuesday, October 15, 2024, 07:33:13
Time Spent: 00:04:41
IP Address: 212.252.138.197

Page 1

Q1 Pediatric Hematology/Oncology Clinic

What is your field of work?

Q2 >10 years

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Izmir

S4 State University

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	>10
Lymphoma	We do not treat
Myeloma	We do not treat

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

<5%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

Including our AML patients, 4

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	2
-----------	---

S9

How many of these patients are able to access CAR-T therapy?

We were only able to arrange it for 1 patient

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

We administered it to one patient diagnosed with PreBCALL

S11

Which CAR-T product was used?

Commercial Product (please specify the product name)	Tisagenlecleucel
Academic Production (specify center)	Frankfurt, Germany. Gowthe Institute

S12

Where did your patient receive CAR-T therapy?

Abroad (specify the center)	Goethe Institute
Overseas work (please specify the center)	The government does not cover it

S13

How long after the indication arose did your patient receive CAR-T therapy?

They were able to receive it on time

S14**Yes**

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#47

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 09:59:39
Last Modified Date: Tuesday, October 15, 2024, 10:03:18 AM
Time Spent: 00:03:38
IP Address: 176.227.16.169

Page 1

Q1 Pediatric Hematology/Oncology Clinic

What is your field of work?

Q2 >10 years

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Istanbul

S4 Public Hospital

The institution where you work;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	c
Lymphoma	None
Myeloma	None

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?
5%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

2

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases	2
Lymphoma count	0
Multiple myeloma count	0

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

None

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Lack of qualified personnel

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

Difficulty accessing treatment

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#48

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 2:52:10 PM
Last Modified Date: Tuesday, October 15, 2024, 2:57:15 PM
Time Spent: 00:05:04
IP Address: 176.236.167.158

Page 1

Q1 Adult Hematology Clinic

What is your area of practice?

Q2 >10 years

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Adana

S4 Foundation University

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	10
Lymphoma	109
Myeloma	52

S6 The respondent skipped this question

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

S7
Based on current guidelines, how many of your patients required CAR-T therapy in the past year?

10

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	4
Lymphoma count	15
Multiple myeloma count	0

S9

How many of these patients have access to CAR-T therapy?

2

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

2, Relapsed/refractory lymphoma

S11

Which CAR-T product was used?

Academic Production (please specify the center)	Israel,
---	---------

S12

Where did your patient receive CAR-T therapy?

Private treatment abroad (specify the center)	Israel,
---	---------

S13

How long after the indication arose did your patient receive CAR-T therapy?

3 months

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Cost

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

Access to treatment

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#49

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 2:59:28 PM
Last Modified Date: Tuesday, October 15, 2024, 3:02:24 PM
Time Spent: 00:02:56
IP Address: 84.51.57.152

Page 1

Q1 **Pediatric Hematology/Oncology Clinic**

What is your field of work?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Kocaeli

S4 **Private Hospital**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	c
Lymphoma	a

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

0%

S7
Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

3

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases

3**S9**

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

None

S11**The respondent skipped this question**

Which CAR-T product was used?

S12**The respondent skipped this question**

Where did your patient receive CAR-T therapy?

S13

How long after the indication arose did your patient receive CAR-T therapy?

0

S14**Yes**

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Insufficient technological infrastructure**

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16**Access issues**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#50

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 3:57:11 PM
Last Modified Date: Tuesday, October 15, 2024, 3:58:32 PM
Elapsed Time: 00:01:21
IP Address: 188.58.100.117

Page 1

Q1 **Adult Hematology Clinic**

What is your field of work?

Q2 **1–5 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Istanbul

S4 **Public Hospital**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	7
Lymphoma	20
Myeloma	30

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

10

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

2

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of lymphoma cases

2

S9

How many of these patients are able to access CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Other

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

Other

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you had access to a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#51

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 3:57:22 PM
Last Modified Date: Tuesday, October 15, 2024, 3:59:22 PM
Time Spent: 00:01:59
IP Address: 176.227.16.139

Page 1

S1 **Adult Hematology Clinic**

What is your area of practice?

S2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Istanbul

S4 **Private Hospital**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	3
Lymphoma	10
Myeloma	10

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

30

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

3

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases	1
Lymphoma count	2
Multiple myeloma count	0

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#52

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 4:02:36 PM
Last Modified Date: Tuesday, October 15, 2024, 4:04:43 PM
Time Spent: 00:02:07
IP Address: 91.93.238.70

Page 1

Q1 **Adult Hematology Clinic**

In which field do you work?

S2 **1–5 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Istanbul

S4 **Public Hospital**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	C
Lymphoma	C
Myeloma	C

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?
50%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

20

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	1
Lymphoma count	6
Multiple myeloma count	13

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#53

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 4:19:13 PM
Last Modified Date: Tuesday, October 15, 2024, 4:20:38 PM
Time Spent: 00:01:24
IP Address: 31.145.40.150

Page 1

Q1 **Adult Hematology Clinic**

What is your field of work?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3

In which city is the organization you work for located?

Istanbul

S4 **Foundation University**

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	10
Lymphoma	80
Myeloma	15

S6 **The respondent skipped this question**

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

S7

Based on current guidelines, how many of your patients required CAR-T therapy in the past year?

2

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of lymphoma cases 1

Multiple myeloma count 1

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Lack of qualified personnel

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

The time it will take to access treatment

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#54

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 4:20:49 PM
Last Modified Date: Tuesday, October 15, 2024, 4:24:13 PM
Time Spent: 00:03:24
IP Address: 95.0.74.47

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the organization you work for located?

Istanbul

S4 **State Hospital**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	16
Lymphoma	100
Myeloma	80

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

30

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

12

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	2
Lymphoma count	8
Multiple myeloma count	2

S9

How many of these patients have access to CAR-T therapy?

0%

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

Which CAR-T product was used?

Commercial Product (please specify the product name)	-
Academic Production (specify center)	-

S12

Where did your patient receive CAR-T therapy?

Abroad (specify the center)	-
Turkey (specify the center)	-
Overseas clinical trial (please specify the center)	-
Work in Turkey (specify location)	-

S13

How long after the indication arose did your patient receive CAR-T therapy?

-

S14**Yes**

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Insufficient technological infrastructure**

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16**Access issues**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#55

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 4:26:07 PM
Last Modified Date: Tuesday, October 15, 2024, 4:28:26 PM
Time Spent: 00:02:19
IP Address: 193.255.88.210

Page 1

Q1 Pediatric Hematology/Oncology Clinic

What is your field of work?

Q2 >10 years

How many years have you been working in the field of hematology?

S3
In which city is the organization you work for located?

Kayseri

S4 State University

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	25
Lymphoma	10
Myeloma	0

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

20

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

7

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases

6

Lymphoma count

2

S9

The respondent skipped this question

How many of these patients have access to CAR-T therapy?

S10

The respondent skipped this question

How many of your patients have received CAR-T therapy?
(Please specify the disease diagnosis and CAR-T indication)

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Lack of qualified personnel

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

Difficulty accessing treatment

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#56

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 4:41:22 PM
Last Modified Date: Tuesday, October 15, 2024, 4:43:19 PM
Time Spent: 00:01:57
IP Address: 194.27.108.19

Page 1

Q1 **Pediatric Hematology/Oncology Clinic**

What is your field of work?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Izmir

S4 **State University**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	b
Lymphoma	b

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

15%

S7
Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

2

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases

2**S9**

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11**The respondent skipped this question**

Which CAR-T product was used?

S12**The respondent skipped this question**

Where did your patient receive CAR-T therapy?

S13**The respondent skipped this question**

How long after the indication arose did your patient receive CAR-T therapy?

S14**Yes**

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

Q17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#57

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 6:43:15 PM
Last Modified Date: Tuesday, October 15, 2024, 6:45:08 PM
Time Spent: 00:01:53
IP Address: 78.165.168.206

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Ankara

S4 **Public Hospital**

The institution where you work;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	c
Lymphoma	c
Myeloma	c

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?
20%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

10

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	1
Lymphoma count	6
Multiple myeloma count	3

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#58

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 7:12:30 PM
Last Modified Date: Tuesday, October 15, 2024, 7:13:09 PM
Time Spent: 00:00:39
IP Address: 5.46.198.11

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

S2 **1–5 years**

How many years have you been working in the field of hematology?

S3 **The respondent skipped this question**

In which city is the institution where you work located?

S4 **The respondent skipped this question**

The organization you work for;

S5 **The respondent skipped this question**

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year?
(a) 5 b) 5–10 c) >10)

S6 **The respondent skipped this question**

What are the relapse rates among patients with these conditions treated at your clinic over the past year?

S7 **The respondent skipped this question**

Based on current guidelines, how many of your patients required CAR-T therapy over the past year?

S8

The respondent skipped this question

How would you categorize your patients who you believe should receive CAR-T therapy based on their diagnoses according to current guidelines?

S9

The respondent skipped this question

How many of these patients are able to access CAR-T therapy?

S10

The respondent skipped this question

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

The respondent skipped this question

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

The respondent skipped this question

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

The respondent skipped this question

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

The respondent skipped this question

If you had access to a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#59

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 7:31:09 PM
Last Modified Date: Tuesday, October 15, 2024, 7:33:12 PM
Time Spent: 00:02:02
IP Address: 176.238.5.152

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **1–5 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Ankara

S4 **Public Hospital**

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	10
Lymphoma	20
Myeloma	15

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

20–30

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

3–4

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	1
Lymphoma count	2
Multiple myeloma count	1

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#60

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 9:12:26 PM
Last Modified Date: Tuesday, October 15, 2024, 9:16:54 PM
Time Spent: 00:04:27
IP Address: 178.240.31.26

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **5–10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Istanbul

S4 **Private Hospital**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	C
Lymphoma	C
Myeloma	C

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

30

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

10–15

S8

Based on current guidelines, how do you determine the distribution of your patients who you believe should receive CAR-T therapy according to their diagnoses?

Number of ALL cases	3
Lymphoma count	10
Multiple myeloma count	2

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

1, primary refractory DLBCL

S11

Which CAR-T product was used?

Academic Institution (please specify the center)	Acıbadem Hospital
--	-------------------

S12

Where did your patient receive CAR-T therapy?

Turkey study (specify center)	Acıbadem Hospital
-------------------------------	-------------------

S13

How long after the indication arose did your patient receive CAR-T therapy?

1–2 months

S14**Yes**

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#61

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 9:18:07 PM
Last Modified Date: Tuesday, October 15, 2024, 10:14:20 PM
Time Spent: 00:56:12
IP Address: 176.40.242.130

Page 1

Q1 **Adult Hematology Clinic**

What is your field of work?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Ankara

S4 **Public Hospital**

The institution where you work;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	>10
Lymphoma	>10
Myeloma	>10

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

15

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

5–10

S8

Based on current guidelines, how do you categorize your patients who you believe should receive CAR-T therapy according to their diagnoses?

Number of lymphoma cases

5–6

Multiple myeloma count

5–6**S9**

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11**The respondent skipped this question**

Which CAR-T product was used?

S12**The respondent skipped this question**

Where did your patient receive CAR-T therapy?

S13**The respondent skipped this question**

How long after the indication arose did your patient receive CAR-T therapy?

S14**Yes**

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

Access to treatment

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#62

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 11:22:25 PM
Last Modified Date: Tuesday, October 15, 2024, 11:24:58 PM
Time Spent: 00:02:32
IP Address: 176.237.241.64

Page 1

Q1 Adult Hematology Clinic

What is your area of practice?

Q2 1–5 years

How many years have you been working in the field of hematology?

S3 In which city is the institution where you work located?

Malatya

S4 State Hospital

The institution where you work;

S5 How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

Lymphoma	A
Myeloma	A

S6 What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

10

S7 Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

0

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of lymphoma cases 1

Multiple myeloma count 1

S9

How many of these patients are able to access CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Cost

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

Access to treatment

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#63

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 11:31:32 PM
Last Modified Date: Tuesday, October 15, 2024, 11:33:46 PM
Time Spent: 00:02:14
IP Address: 88.242.132.251

Page 1

Q1 Adult Hematology Clinic

What is your area of practice?

Q2 1–5 years

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Manisa

S4 State University

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	c
Lymphoma	c
Myeloma	c

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?
20–40

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

5

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases	0
Lymphoma count	4
Multiple myeloma count	1

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many patients have you treated with CAR-T therapy? (Please specify the disease diagnosis and the indication for CAR-T therapy)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

The respondent skipped this question

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#64

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Tuesday, October 15, 2024, 11:31:59 PM
Last Modified Date: Tuesday, October 15, 2024, 11:36:49 PM
Time Spent: 00:04:50
IP Address: 78.177.160.135

Page 1

Q1 Pediatric Hematology/Oncology Clinic

What is your field of work?

Q2 >10 years

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Istanbul

S4 State University

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at your clinic in the past year? (a) 5 b) 5–10 c) >10)

ALL	>10
Lymphoma	5–10
Myeloma	0

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

1

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

0

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases

0

S9

How many of these patients have access to CAR-T therapy?

1

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

1 (B-ALL, recurrent CNS relapse)

S11

Which CAR-T product was used?

Academic Production (please specify the center)

Acibadem University (Ercüment Ovalı)

S12

Where did your patient receive CAR-T therapy?

Turkey (specify center)

Acibadem University (Ercüment Ovalı)

S13

How long after the indication arose did your patient receive CAR-T therapy?

6 months

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15 **Insufficient technological infrastructure**

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16 **Difficulty accessing treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17 **Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#65

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Wednesday, October 16, 2024, 08:44:07
Last Modified Date: Wednesday, October 16, 2024, 08:46:59
Time Spent: 00:02:51
IP Address: 193.140.54.66

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Adana

S4 **State University**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at your clinic in the past year? (a) 5 b) 5–10 c) >10)

ALL	c
Lymphoma	c
Myeloma	c

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

21

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

15

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	1
Lymphoma count	8
Multiple myeloma count	12

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#66

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Wednesday, October 16, 2024, 2:37:48 PM
Last Modified Date: Wednesday, October 16, 2024, 2:40:12 PM
Time Spent: 00:02:24
IP Address: 5.23.123.117

Page 1

Q1 Pediatric Hematology/Oncology Clinic

What is your field of work?

Q2 >10 years

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Ankara

S4 State University

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	>10
Lymphoma	Oncology is following up. I don't know

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

10% in ALL

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

1

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases

1

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15

Cost

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16

You do not believe it will make a meaningful difference in efficacy

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17

Yes

If you had access to a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#67

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Wednesday, October 16, 2024, 7:51:23 PM
Last Modified Date: Wednesday, October 16, 2024, 7:53:36 PM
Time Spent: 00:02:13
IP Address: 78.163.118.108

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **5–10 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Istanbul

S4 **Public Hospital**

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	0
Lymphoma	20
Myeloma	20

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

-/5%/30%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

-/1/-

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases	0
Lymphoma count	1
Multiple myeloma count	0

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

Which CAR-T product was used?

Commercial Product (please specify the product name)	0
--	---

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

The respondent skipped this question

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Lack of qualified personnel**

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16**Serious side effects**

What is your reason for not referring a patient with a CAR-T indication for treatment?

Q17**Yes**

If you had access to a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#68

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Wednesday, October 16, 2024, 9:39:36 PM
Last Modified Date: Wednesday, October 16, 2024, 9:41:51 PM
Time Spent: 00:02:14
IP Address: 46.106.161.51

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **1–5 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Ankara

S4 **Public Hospital**

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	C
Lymphoma	C
Myeloma	C

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

35%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

12

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	5
Lymphoma count	5
Multiple myeloma count	2

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

The respondent skipped this question

Are the challenges in accessing CAR-T therapy preventing you from offering it as an option to your patients?

S15 **Insufficient technological infrastructure**

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16 **Access issues**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17 **Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#69

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Wednesday, October 16, 2024, 9:51:09 PM
Last Modified Date: Wednesday, October 16, 2024, 9:56:01 PM
Time Spent: 00:04:52
IP Address: 81.214.204.150

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **>10 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Istanbul

S4 **State University**

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	c
Lymphoma	c
Myeloma	c

S6

What is the relapse rate among patients with these disease groups treated at your clinic in the past year?

50%

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

20

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	<5
Lymphoma count	5–10
Multiple myeloma count	10–15

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15	Insufficient technological infrastructure
------------	--

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16	Access issues
------------	----------------------

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17	Yes
------------	------------

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#70

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Wednesday, October 16, 2024, 10:00:32 PM
Last Modified Date: Wednesday, October 16, 2024, 10:02:31 PM
Time Spent: 00:01:59
IP Address: 5.176.98.88

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **1–5 years**

How many years have you been working in the field of hematology?

S3

In which city is the institution where you work located?

Izmir

S4 **State University**

The institution you work for;

S5

How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	20
Lymphoma	100
Myeloma	200

S6

What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

40

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

20

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	3
Lymphoma count	18
Multiple myeloma count	4

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

How long after the indication arose did your patient receive CAR-T therapy?

0

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Other**

What is the biggest barrier to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?

#71

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Thursday, October 17, 2024, 8:13:09 PM
Last Modified Date: Thursday, October 17, 2024, 8:15:42 PM
Time Spent: 00:02:33
IP Address: 46.155.77.191

Page 1

Q1 **Adult Hematology Clinic**

What is your area of practice?

Q2 **1–5 years**

How many years have you been working in the field of hematology?

S3
In which city is the institution where you work located?

Ankara

S4 **State University**

The institution you work for;

S5
How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	c
Lymphoma	c
Myeloma	c

S6
What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

40

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy over the past year?

3

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

Number of ALL cases	0
Lymphoma count	3
Multiple myeloma count	0

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

aggressive B-cell lymphoma; refractory to multiple treatments

S11

Which CAR-T product was used?

Commercial Product (please specify the product name)	0
Academic Production (specify center)	0

S12

Where did your patient receive CAR-T therapy?

Abroad (specify the center)	0
Turkey (specify the center)	0
Overseas clinical trial (please specify the center)	0
Work in Turkey (specify location)	0

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14	Yes
Are the challenges in accessing CAR-T therapy preventing you from offering this treatment as an option to your patients?	
S15	Insufficient technological infrastructure
What is the biggest obstacle to accessing CAR-T therapy in Turkey?	
S16	Access issues
What is your reason for not referring a patient with a CAR-T indication for treatment?	
S17	Yes
If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?	

#72

COMPLETED

Collector: Web Link 1 (Web Link)
Start Time: Saturday, October 19, 2024, 10:10:28 PM
Last Modified Date: Saturday, October 19, 2024, 10:24:11 PM
Time Spent: 00:13:42
IP Address: 85.106.185.50

Page 1

Q1 Adult Hematology Clinic

What is your area of practice?

Q2 >10 years

How many years have you been working in the field of hematology?

S3 In which city is the institution where you work located?

KAYSERİ

S4 State University

The institution you work for;

S5 How many patients with pre-B-ALL, B-NHL, and myeloma were treated at the clinic where you work in the past year? (a) 5 b) 5–10 c) >10)

ALL	5
Lymphoma	20
Myeloma	25

S6 What are the relapse rates among patients with these disease groups treated at your clinic in the past year?

30

S7

Based on current guidelines, how many of your patients would have required CAR-T therapy in the past year?

5

S8

How would you categorize the diagnoses of the patients you believe should receive CAR-T therapy according to current guidelines?

ALL count	3
Lymphoma count	1
Multiple myeloma count	1

S9

How many of these patients have access to CAR-T therapy?

0

S10

How many of your patients have received CAR-T therapy? (Please specify the disease diagnosis and CAR-T indication)

0

S11

The respondent skipped this question

Which CAR-T product was used?

S12

The respondent skipped this question

Where did your patient receive CAR-T therapy?

S13

The respondent skipped this question

How long after the indication arose did your patient receive CAR-T therapy?

S14

Yes

Do the challenges in accessing CAR-T therapy prevent you from offering this treatment as an option to your patients?

S15**Cost**

What is the biggest obstacle to accessing CAR-T therapy in Turkey?

S16**Access to treatment**

What is your reason for not referring a patient with a CAR-T indication for treatment?

S17**Yes**

If you could access it through a national and/or international clinical trial, would you want to use CAR-T therapy for your relapsed patients?
